Pacific Biosciences of California PACB Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $14.76M-38.0% | $23.78M-27.2% | $32.68M+328% | $7.64M+8,113% | ||
| -$546.38M-75.0% | -$312.22M-1.8% | -$306.74M+2.4% | -$314.25M-73.4% | ||
| -$171.43M+60.4% | -$433.13M-37.6% | -$314.74M-6.0% | -$296.8M-46.3% | ||
| -$553.86M-16.8% | -$474.31M-41.8% | -$334.47M-8.9% | -$307.2M-46.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacific Biosciences of California's revenue?
- Pacific Biosciences of California (PACB) generated $160.0M in revenue over the trailing twelve months, up 5.0% year over year.
- Is Pacific Biosciences of California profitable?
- Pacific Biosciences of California is not currently profitable: it reported a net loss of $128.6M over the trailing twelve months, a -80.3% net margin.
- What are Pacific Biosciences of California's profit margins?
- Gross margin is 37.5% and operating margin is -83.3%, with a -80.3% net margin.
- What is Pacific Biosciences of California's earnings per share?
- Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
- Where does Pacific Biosciences of California's income statement data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
